Sage Journals: Discover world-class research

Abstract

Purpose

To report midterm results of 3 cases in which drug-eluting balloons (DEBs) were successfully used for the management of carotid in-stent restenosis (ISR).

Case Report

Two women aged 68 and 70 years and a 68-year-old man were referred to our institution for asymptomatic severe stenosis [>80% with peak systolic velocity (PSV) >300 cm/s by Doppler ultrasound assessment] of individual Carotid Wallstents implanted in the proximal left internal carotid artery (ICA). In the angiosuite, the left ICA was engaged in a telescopic fashion with a triple coaxial system formed by a 6-F long sheath and a preloaded 5-F, 125-cm diagnostic catheter over a 0.035-inch soft hydrophilic guidewire. Under distal filter protection, the lesions were predilated using a 3.5×20-mm coronary balloon and then treated with two 1-minute inflations of a 4×40-mm Amphirion In.Pact paclitaxel-eluting balloon, followed by 3 months of dual antiplatelet therapy. At 12, 22, and 36 months, respectively, the patients are still asymptomatic, with duplex-documented stent patency at 6, 12, and 24 months, respectively.

Conclusion

DEBs are an emerging strategy for carotid ISR, with encouraging midterm results in these patients. Further experience in larger cohorts is needed to confirm these preliminary observations.

Keywords

drug-eluting balloon carotid stent paclitaxel stenosis in-stent restenosis

Get full access to this article

View all access options for this article.

References

Gray

White

Barrett

. Carotid stenting and endarterectomy. A clinical and cost comparison of revascularization strategies. Stroke. 2002;33:1063–1070.

Rajagopal

Yadav

. Management of carotid artery disease in the high-risk patient with emphasis on the SAPPHIRE study. Curr Cardiol Rep. 2007;9:20–24.

Massop

Dave

Metzger

; on behalf of the SAPPHIRE Worldwide Investigators. Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy: SAPPHIRE worldwide registry first 2,001 patients. Catheter Cardiovasc Interv. 2008;73:129–136.

AbuRahma

. Commentary: The incidence of carotid in-stent stenosis is underestimated: should it be treated or left alone? J Endovasc Ther. 2011;18:726–728.

van Haaften

Bots

Moll

. Therapeutic options for carotid in-stent restenosis: review of the literature. J Vasc Interv Radiol. 2010;21:1471–1477.

Brott

Hobson

Howard

. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11–23.

Lal

Kaperonis

Cuadra

. Patterns of in-stent restenosis after carotid artery stenting: classification and implications for long-term outcome. J Vasc Surg. 2007;46:833–840.

Banning

Lim

. Drug-eluting balloons: what is their place on the interventionalist's shelf? Heart. 2010;96:1257–1258.

Waksman

Pakala

. Drug-eluting balloon: the comeback kid? Circ Cardiovasc Interv. 2009;2:352–358.

10.

Tian

Kuhlmann

Pelisek

. Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model. J Endovasc Ther. 2006;13:616–629.

11.

Scheller

Speck

Abramjuk

. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810–814.

12.

Scheller

Hehrlein

Bocksch

. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113–2124.

13.

Fanelli

Cannavale

Boatta

. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the Debellum randomized trial. J Endovasc Ther. 2012;19:571–580.

14.

Vajda

Guthe

Perez

. Neurovascular in-stent stenoses: treatment with conventional and drug-eluting balloons. AJNR Am J Neuroradiol. 2011;32:1942–1947.

15.

Ventoruzzo

Biondi-Zoccai

Maioli

. A tailored approach to overcoming challenges of a bovine aortic arch during left internal carotid artery stenting. J Endovasc Ther. 2012;19:329–338.

Drug-Eluting Balloon Angioplasty for Carotid In-Stent Restenosis